Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

35.68USD
22 Feb 2018
Change (% chg)

$-0.08 (-0.22%)
Prev Close
$35.76
Open
$35.87
Day's High
$36.15
Day's Low
$35.61
Volume
12,301,165
Avg. Vol
19,533,373
52-wk High
$39.43
52-wk Low
$31.67

Latest Key Developments (Source: Significant Developments)

EMD Serono Says Health Canada Approves BAVENCIO For Treating Metastatic Merkel Cell Carcinoma
11:30am EST 

Feb 22 (Reuters) - EMD Serono::EMD SERONO - CO, PFIZER CANADA ANNOUNCE HEALTH CANADA APPROVAL FOR BAVENCIO FOR TREATING METASTATIC MERKEL CELL CARCINOMA IN PREVIOUSLY TREATED ADULTS.  Full Article

Spark Therapeutics Enters Into A Spk-9001 Manufacture And Supply Agreement With Pfizer
Tuesday, 20 Feb 2018 08:22am EST 

Feb 20 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING.SPARK THERAPEUTICS SAYS UNDER AGREEMENT, PFIZER WILL PAY CO $7 MILLION UPON EXECUTION OF AGREEMENT - SEC FILING.SPARK THERAPEUTICS INC - THE AGREEMENT IS TO MANUFACTURE AND DELIVER TO PFIZER SPARK-9001 BULK DRUG SUBSTANCE.SPARK THERAPEUTICS INC - UNDER AGREEMENT, PFIZER MAY MAKE A SECOND PAYMENT TO CO OF UP TO $7 MILLION.SPARK THERAPEUTICS INC - CO WILL BEGIN SPARK-9001 BULK DRUG SUBSTANCE MANUFACTURE IN THE FIRST QUARTER OF 2018.  Full Article

Reckitt CEO bullish on consumer health, no comment on Pfizer
Monday, 19 Feb 2018 02:38am EST 

Feb 19 (Reuters) - Reckitt Benckiser Group Plc ::RECKITT BENCKISER CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTH AUCTION.RECKITT BENCKISER CEO SAYS ACQUISITIONS MUST BE STRATEGICALLY COMPELLING, RB MUST BE A BETTER OWNER, AND MUST DRIVE VALUE FOR SHAREHOLDERS.RECKITT BENCKISER CEO SAYS CONFIDENT ABOUT GROWTH OF CONSUMER HEALTH CATEGORY IN LONG TERM.  Full Article

Pfizer Receives Breakthrough Therapy Designation From FDA For Atopic Dermatitis Treatment, PF-04965842
Wednesday, 14 Feb 2018 08:30am EST 

Feb 14 (Reuters) - Pfizer Inc ::PFIZER RECEIVES BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PF-04965842, AN ORAL JAK1 INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.  Full Article

Pfizer says U.S., EU And Japan Health Authorities Accept Lorlatinib For Review
Monday, 12 Feb 2018 08:00am EST 

Feb 12 (Reuters) - Pfizer Inc ::U.S., EU AND JAPAN HEALTH AUTHORITIES ACCEPT REGULATORY SUBMISSIONS FOR REVIEW OF PFIZER’S THIRD-GENERATION ALK INHIBITOR LORLATINIB.PFIZER INC - U.S. NEW DRUG APPLICATION FOR LORLATINIB GRANTED FDA PRIORITY REVIEW.  Full Article

GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences
Thursday, 8 Feb 2018 02:00am EST 

Feb 8 (Reuters) - Glaxosmithkline Plc ::VIIV FILES PATENT INFRINGEMENT LITIGATION.GLAXOSMITHKLINE PLC - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​.  Full Article

ViiV Healthcare files patent infringement litigation against Gilead Sciences
Wednesday, 7 Feb 2018 04:15pm EST 

Feb 7 (Reuters) - :VIIV HEALTHCARE FILES PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR.VIIV HEALTHCARE - FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN THE UNITED STATES AND CANADA.VIIV HEALTHCARE - WILL SEEK TO PROVE THAT GILEAD'S TRIPLE COMBINATION HIV DRUG INFRINGES CO'S PATENT COVERING DOLUTEGRAVIR AND MANY OTHER COMPOUNDS.VIIV HEALTHCARE - VIIV HEALTHCARE WILL SEEK FINANCIAL REDRESS FOR PATENT INFRINGEMENT.  Full Article

GSK CEO says will take serious look at major consumer health assets
Wednesday, 7 Feb 2018 07:00am EST 

Feb 7 (Reuters) - Glaxosmithkline CEO Emma Walmsley tells reporters::CEO SAYS OBVIOUSLY EXPECTING MORE COMPETITION IN HIV THIS YEAR.CEO SAYS FIRST PRIORITY IS PHARMA RESEARCH AND DEVELOPMENT, WHICH COULD INCLUDE EARLY-STAGE DRUG DEALS.CEO SAYS NEXT PRIORITY IS CONSUMER PUT FROM NOVARTIS, IF IT COMES.CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTHCARE AUCTION BUT SHOULD EXPECT GSK TO TAKE SERIOUS LOOK AT MAJOR CONSUMER ASSETS.CEO SAYS BIG CONSUMER HEALTH DEAL 'NOT A NEED TO DO'.CEO SAYS BELIEVES SHINGRIX WILL BE BIGGEST VACCINE FOR GSK OVER MEDIUM TO LONG TERM.CEO SAYS 'WE KNOW DIVIDEND MATTERS TO OUR SHAREHOLDERS'.CEO SAYS MOST IMPORTANT THING ON BREXIT IS TO GET A TRANSITION PERIOD OF AT LEAST 2 YEARS, SECURED BY APRIL 2018.CEO SAYS ON BREXIT INDUSTRY NEEDS MUTUAL RECOGNITION, CLOSE WORK WITH EMA, MINIMAL TRADE FRICTION, CONTINUED RESEARCH AND DEVELOPMENT COLLABORATION WITH EU.  Full Article

‍NetVation DL Medicine announces research collaboration with Pfizer Inc
Tuesday, 6 Feb 2018 05:09am EST 

Feb 6 (Reuters) - NetVation DL Medicine::‍NETVATION DL MEDICINE -ENTERED INTO A TWO-YEAR RESEARCH COLLABORATION WITH PFIZER INC.NETVATION DL SAYS ‍AS PART OF COLLABORATION, PFIZER HAS TAKEN A FINANCIAL STAKE IN DL MEDICINE.​.  Full Article

Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
Tuesday, 16 Jan 2018 07:00am EST 

Jan 16 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO.FOUNDATION MEDICINE - PARTNERSHIP FOCUSES ON DEVELOPMENT, REGULATORY SUPPORT AND COMMERCIALIZATION OF COMPANION DIAGNOSTICS.FOUNDATION MEDICINE - CENTERS FOR MEDICARE & MEDICAID SERVICES ISSUED PRELIMINARY NATIONAL COVERAGE DETERMINATION FOR FOUNDATIONONE CDX.FOUNDATION MEDICINE INC - FINAL POLICY FOR FOUNDATIONONE CDX IS EXPECTED TO ISSUE DURING Q1 OF 2018.  Full Article

BRIEF-Spark Therapeutics Enters Into A Spk-9001 Manufacture And Supply Agreement With Pfizer

* SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING